Illumina Inc. (NASDAQ: ILMN) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study published today in Science illustrates how this deep learning technology discovered regulatory variants in noncoding "promoter" segments that contribute up to 6% of the genetic causes of rare diseases. By turning data into insights, this technology is expected to help researchers accelerate new breakthroughs in diagnosis for rare diseases.

On September 6th, Roche Diagnostics China announced its official partnership with Deep Informatics. They will jointly launch a pathology artificial intelligence (AI) assisted interpretation algorithm product, further promoting the digitalization and intelligent transformation of pathology diagnosis in China, providing strong support for the development of personalized precision diagnosis and treatment.

Roche said on Friday that it has entered into a collaboration with Bristol Myers Squibb to develop and deploy two assays with new digital pathology algorithms for clinical trials.